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Summary
Background Surgery is the main modality of cure for solid cancers and was prioritised to continue during COVID-19 
outbreaks. This study aimed to identify immediate areas for system strengthening by comparing the delivery of 
elective cancer surgery during the COVID-19 pandemic in periods of lockdown versus light restrictions.
Methods This international, prospective, cohort study enrolled 20 006 adult (≥18 years) patients from 466 hospitals in 
61 countries with 15 cancer types, who had a decision for curative surgery during the COVID-19 pandemic and were 
followed up until the point of surgery or cessation of follow-up (Aug 31, 2020). Average national Oxford COVID-19 
Stringency Index scores were calculated to define the government response to COVID-19 for each patient for the 
period they awaited surgery, and classified into light restrictions (index <20), moderate lockdowns (20–60), and full 
lockdowns (>60). The primary outcome was the non-operation rate (defined as the proportion of patients who did not 
undergo planned surgery). Cox proportional-hazards regression models were used to explore the associations between 
lockdowns and non-operation. Intervals from diagnosis to surgery were compared across COVID-19 government 
response index groups. This study was registered at ClinicalTrials.gov, NCT04384926.
Findings Of eligible patients awaiting surgery, 2003 (10·0%) of 20 006 did not receive surgery after a median follow-up 
of 23 weeks (IQR 16–30), all of whom had a COVID-19-related reason given for non-operation. Light restrictions were 
associated with a 0·6% non-operation rate (26 of 4521), moderate lockdowns with a 5·5% rate (201 of 3646; adjusted 
hazard ratio [HR] 0·81, 95% CI 0·77–0·84; p<0·0001), and full lockdowns with a 15·0% rate (1775 of 11 827; HR 0·51, 
0·50–0·53; p<0·0001). In sensitivity analyses, including adjustment for SARS-CoV-2 case notification rates, moderate 
lockdowns (HR 0·84, 95% CI 0·80–0·88; p<0·001), and full lockdowns (0·57, 0·54–0·60; p<0·001), remained 
independently associated with non-operation. Surgery beyond 12 weeks from diagnosis in patients without 
neoadjuvant therapy increased during lockdowns (374 [9·1%] of 4521 in light restrictions, 317 [10·4%] of 3646 in 
moderate lockdowns, 2001 [23·8%] of 11 827 in full lockdowns), although there were no differences in resectability 
rates observed with longer delays.
Interpretation Cancer surgery systems worldwide were fragile to lockdowns, with one in seven patients who were in 
regions with full lockdowns not undergoing planned surgery and experiencing longer preoperative delays. Although 
short-term oncological outcomes were not compromised in those selected for surgery, delays and non-operations 
might lead to long-term reductions in survival. During current and future periods of societal restriction, the resilience 
of elective surgery systems requires strengthening, which might include protected elective surgical pathways and long-
term investment in surge capacity for acute care during public health emergencies to protect elective staff and services.
Funding National Institute for Health Research Global Health Research Unit, Association of Coloproctology of Great 
Britain and Ireland, Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper 
Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European 
Society of Coloproctology, Medtronic, Sarcoma UK, The Urology Foundation, Vascular Society for Great Britain and 
Ireland, and Yorkshire Cancer Research.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
During the COVID-19 pandemic, government restrictions 
have aimed to control community SARS-CoV-2 trans-
mission and included reducing population movement, 
closing public facilities, and restricting gatherings.1 
Restrictions have varied worldwide in stringency, with the 
most severe leading to so-called lockdowns.2 Although 
public and media attention has largely focussed on the 
economic impact of lockdowns, the broader effects on 
general health are poorly understood.3 Lockdowns might 
have had collateral effects beyond controlling community 
SARS-CoV-2 rates alone, due to changes in both public 
behaviour and health system performance.4 These 
might have disproportionate effects on vulnerable and 
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marginalised communities.5,6 Understanding these effects 
will justify expenditure on targeted system strengthening, 
as further societal restrictions are predicted at a global 
level.
In the first COVID-19 waves (ie, the 12 weeks of peak 
disruption), at least 21 million elective operations were 
cancelled globally, partly due to concerns over post-
operative SARS-CoV-2 infection and partly due to capacity 
issues within hospitals.7,8 There was, however, general 
guidance from health ministries and national surgical 
associations that time-dependent surgery should 
continue.9 This included curative cancer surgery, which 
is a priority among the oncology com munity and a high-
value topic for society.10,11 Surgery remains the primary 
method of cure for most solid cancers.
Since surgical databases and cancer registries do not 
capture prospective decision making, they lack fidelity to 
detect patients who did not undergo planned surgery. In 
the case of curative surgery, these are the patients who 
might have suffered the most harm.12,13 Resection 
margins alone are an inadequate marker of success, as 
selection bias in patients who are able to undergo surgery 
risks underestimating harm from treatment delays, and 
neglects whole-system effects. We planned the 
prospective COVIDSurg Cancer study to address these 
areas and provide an accurate, whole-system analysis of 
the impact of COVID-19 on planned cancer surgery. 
Understanding any harms could allow for immediate 
local and national policy changes, in preparation for 
future societal restrictions.
Methods
Study design and participants
This international, multicentre, prospective cohort study 
included adult patients (≥18 years) with a diagnosis of a 
surgically curable cancer during the COVID-19 
pandemic. The study was conducted in accordance with a 
preregistered protocol (NCT04384926). Local principal 
investigators were responsible for obtaining clinical 
audit, institutional review board, or ethical approval in 
line with local and national regulations. In most settings, 
a waiver of individual patient consent was obtained. In 
other countries, formal written or verbal consent was 
required based on recommendations of local ethics and 
governance committees. Data were collected online and 
stored on a secure server running the Research Electronic 
Data Capture (REDCap) web application.14
Any hospital worldwide that performed elective cancer 
surgery in an area affected by the COVID-19 pandemic 
was eligible to participate. Patients listed for surgery to 
cure a solid cancer were included in each centre for 
3 months from local emergence of COVID-19, defined on 
a centre-by-centre basis as the date where first notification 
of SARS-CoV-2 cases occurred in the local area (between 
Jan 21 and April 14, 2020). Participating centres identified 
all patients with a decision for surgery (or would have 
had a decision for surgery under normal, prepandemic 
circumstances) from multidisciplinary team meetings, 
tumour board, outpatient clinics, or local equivalents. 
Previous international outcomes studies from our group 
have shown that this method achieves greater than 
Research in context
Evidence before this study
Guidance from health ministries and national surgical 
associations prioritised time-dependent cancer surgery to 
continue during societal restrictions related to COVID-19. 
We searched PubMed and Embase on Feb 12, 2021, without date 
limits, for prospective, multicountry studies describing non-
operation rates for patients planned to undergo elective surgery 
during national or regional COVID-19 lockdowns using primary 
data. We used the search terms “COVID-19”, “SARS-CoV-2”, 
“coronavirus”, “lockdown” and “pandemic”, in combination with 
“surgery” and “non-operation”, “cancellation”, “postponement” 
or “delays”, and applied no language restrictions. Several 
modelling studies estimated total elective surgeries cancelled due 
to COVID-19, but no primary studies described the impact of 
lockdowns on non-operation rates for patients due to undergo 
curative cancer surgery.
Added value of this study
There is limited evidence of the collateral effects of COVID-19 
pandemic lockdowns outside of modelling studies. Uniquely, 
this international study prospectively enrolled patients with a 
decision for curative surgery awaiting surgery during the 
SARS-CoV-2 pandemic and tracked their care pathways 
prospectively. It included data from the 15 most common solid 
cancer types across all country-income settings, providing wide 
generalisability to global policy. The analysis allowed a direct 
comparison of full and moderate lockdowns to light 
restrictions, accounting for their dynamic nature, where 
different patients from the same country were exposed to 
different lockdown states.
Implications of all the available evidence
This study has direct policy, organisational, and clinical 
implications. It has revealed the fragility of elective cancer surgery 
systems to lockdowns, particularly health systems in lower-
middle-income countries. This study demonstrates the need for 
system strengthening in elective surgery across all settings to 
mitigate against impending COVID-19 lockdowns and future 
pandemics. This should include both global reorganisation to 
provide protected COVID-19-free elective surgical pathways 
(and staffing) that sustainably allow safe surgery to continue, 
and improved surge capacity for acute care during public health 
emergencies. The potential long-term effects for patients who 
underwent delayed surgery may require closer follow-up for 
metastatic disease. This study could inform policy makers’ 
planning regarding the collateral effects of societal restrictions.
For the protocol see https://
globalsurg.org/cancercovidsurg/
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95% case ascertainment and greater than 98% data 
accuracy during external validation.15 If a specialty within 
a hospital was unable to confirm consecutive enrolment, 
their data were excluded from analysis. Patients’ care 
pathways were followed up until the point of surgery or 
until cessation of follow-up at Aug 31, 2020. This date 
was selected to ensure all patients had a minimum of 
12-weeks follow-up. Where a patient underwent surgery, 
outcome data was collected up to 30 days after surgery. 
Where patients remained non-operated, their last known 
status was recorded.
The 15 most common solid cancer types were included 
in this study, including colorectal, oesophageal, gastric, 
head and neck (oral, oropharyngeal, laryngeal, hypo-
pharyngeal, salivary, thyroid, paranasal sinus, skin), 
thoracic (lung, pleural, mediastinal, chest wall), liver, 
pancreatic, prostate, bladder, renal and upper urinary 
tract urothelial, gynaeco logical (uterine, ovarian, cervical, 
vulval, vaginal), breast, soft-tissue sarcoma, bony sarcoma, 
and intracranial malignancies. Participating centres could 
contribute data for either single or multiple cancers. Early 
cancers that were planned to be managed with endo-
scopic surgery alone (eg, transurethral resection of 
bladder tumour, transanal endoscopic micro surgery) 
were excluded. Patients who were suspected to have an 
operable cancer, but were later identified to have a 
non-cancerous condition (eg, on postoperative histo-
pathology), or were treated as benign and unexpectedly 
identified to be malignant on postoperative histopathology 
were also excluded.
Definition of lockdowns
We used the Oxford COVID-19 Stringency Index to 
define each country’s national government response to 
COVID-19. This index is a composite of 19 indicators 
including measures and behavioural interventions 
related to containment and closure, economic response, 
and health systems. Each indicator is scored using an 
ordinal scale (0 to 2, 3, 4, or 5), with an overall score 
calculated by adding together individual indicator scores 
(appendix p 56). Total scores can range from 0 (no 
restrictions) to 100 (most stringent restrictions). The 
index has been previously validated by demonstrating 
associations with population SARS-CoV-2 infection rates 
and mobile phone mobility data.1
The average national Oxford COVID-19 Stringency 
Index scores were calculated for each patient for the 
period they waited for surgery. To define cutoffs that were 
reflective of real-world policy, we sampled reported 
lockdown dates from a sample of high-income countries, 
upper-middle-income countries (UMICs), and lower-
middle-income countries (LMICs; appendix p 55). Dates 
were taken from national policy, media, and press 
sources. On the date of transition into lockdown, the 
point estimate for the COVID-19 Stringency Index score 
was extracted (appendix p 55). This point estimate was 
used to classify patients into three stringency groups: 
light restrictions (index <20), moderate lockdowns 
(20–60), and full lockdowns (>60). These groups allowed 
a direct com parison of full and moderate lockdowns to 
light restrictions, accounting for their dynamic nature, 
whereby different patients from the same country were 
exposed to different lockdown states. For each patient, a 
median average score while waiting for surgery and the 
number of weeks in full lockdown were calculated 
and used in analyses. Full details are given in the 
appendix (pp 2, 57–58).
Definition of SARS-CoV-2 rates
The case notification rate was calculated at an individual 
patient level as a median average between the date of 
local emergence of COVID-19 and the date of surgery or 
cessation of follow-up via the Our World in Data portal.16 
A high COVID-19 burden area was classified as a median 
of at least 25 cases per 100 000 per 14 days, representing 
WHO recommendations at the time of the study (ie, in 
keeping with first pandemic wave levels). Case rates were 
used for exploratory analyses only, and stratified by World 
Bank income tertile (appendix p 58).17,18
Other definitions
The World Bank index (2019/20 update) was used to 
classify countries and patients into three groups based 
on Gross National Income per capita (US$) calculated 
using the Atlas method: high-income countries, UMICs, 
and LMICs (including patients from both low-income 
countries and LMICs). Data on baseline patient status 
was collected for the purpose of adjustment for case-mix 
in exploring associations between lockdowns and 
surgical capacity (appendix p 59).
Patients were classified into three groups according to 
their neoadjuvant treatment group: (1) no neoadjuvant 
therapy (ie, straight to surgery); (2) neoadjuvant therapy, 
standard care (where the treating clinician administered 
neoad juvant treatment in accordance with their usual 
care); (3) neoadjuvant therapy, COVID-19 decision 
(where the treating clinician administered a neoadjuvant 
treatment where this would not typically be indicated). To 
estimate the impact of lockdown on treatment delays, the 
relationship between lockdowns and the interval from 
diagnosis to decision for surgery to surgery was 
measured. The interval from date of diagnosis to the date 
of surgery was calculated in whole weeks to identify 
points of system friction (appendix p 60).
Outcomes
A resilient elective surgical care system is defined as a 
hospital or network of hospitals that is able to maintain 
both its capacity and safety during public health crises.19 
As a measure of the ability of surgical systems to 
maintain their capacity, the primary outcome measure 
was the non-operation rate. This non-operation rate was 
defined as an eligible patient (ie, with a plan to undergo 
surgery) not undergoing their planned operation during 
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the study window. Patients were classified as being 
operated if they underwent surgery, regardless of whether 
there was a change to the planned urgency (eg, from 
elective to emergency) or intent (eg, from curative 
to palliative). Patients who died or progressed to 
unresectable disease before surgery were classified as 
non-operated, so these did not act as competing risks.
For patients who did not receive their surgery as 
planned during the follow-up window, the treating 
clinical team selected one or more reasons that the 
patient had not had surgery. These reasons included 
those explicitly COVID-19 related (eg, decision to delay 
surgery due to patient risk during COVID-19), and those 
non-COVID-19 related (eg, delay due to other unrelated 
medical or surgical condition). More than one reason for 
non-operation could be selected for each patient, 
representing the complexity of decision making (full 
details are given in the appendix p 61).
Secondary outcome measures related to safety of surgery 
were presented for patients who underwent surgery during 
the follow-up period: (1) resection margin status for those 
selected for surgery; (2) resectable disease at the time of 
surgery; (3) preoperative cancer compli cation requiring 
emergency surgery; (3) 30-day post operative SARS-CoV-2 
infection rate; (4) 30-day post operative mortality rate; 
(5) new detection of metastatic disease up to a maximum 
of 30 days after surgery. As neoadjuvant therapy has a 
complex interplay with treatment interval, an a-priori 
decision was made to only include patients who went 
straight to surgery (no neoadjuvant therapy) in exploration 
of the effects of treatment delay on secondary outcomes 
(appendix p 62).
Statistical analysis
The full statistical method is presented in the 
appendix (p 63). Cox proportional hazards regression 
modelling was used to explore associations between 
lockdowns and the primary outcome, presented as 
adjusted hazard ratios (HRs) and 95% CIs. Operation 
was included as the outcome event, and no censoring 
was performed for death or progression to unresectable 
disease to deal with competing risks, given individuals 
had the same follow-up time (ie, describing sub-
distribution rather than cause-specific hazards). An 
α level was set at 0·05 (5%) for interpretation of 
significance. Several preplanned sensitivity analyses 
were conducted for the primary analysis to examine 
robustness of findings; namely, (1) including elective 
operations only in the definition of the primary outcome; 
(2) accounting for an interaction effect between World 
Bank income group and COVID-19 stringency index 
group; and (3) accounting for local SARS-CoV-2 case 
notification rates, stratified by World Bank income group. 
Two further sensitivity analyses were performed to 
Figure 1: Flowchart of included patients
*Found clinically, radiologically, or during surgery.
27 700 patients identified from multidisciplinary team meeting (or equivalent)
15 622 no neo-
 adjuvant
 therapy
4727 <4 weeks from diagnosis to
 surgery




5597 5–8 weeks from diagnosis to
 surgery
 87 unresectable disease*
2601 9–12 weeks from diagnosis to
 surgery
 46 unresectable disease*
2697 >12 weeks from diagnosis to
 surgery
 52 unresectable disease*














20 006 adult patients with decision for curative cancer surgery (61 countries, 466 centres)
7694 excluded
 764 surgery planned with palliative intent
 2466 diagnosis made after surgery
 840 diagnosis made after decision for surgery
 1859 carcinoma in situ (Tis/Ta)
 222 planned redo resection
 883 intracranial tumours
 660 local resection only
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ensure that differences in cancer case-mix across income 
settings were not responsible for residual confounding; 
these included, (1) cancer location removed from the 
model; and (2) patients older than 50 years only. 
A secondary analysis was used to explore the incremental 
effect of weeks in lockdown on a patient’s likelihood of 
non-operation. Intervals from diagnosis to surgery were 
compared across COVID-19 government response index 
groups. We only analysed the interval between diagnosis 
and surgery for patients who did not receive neo-adjuvant 
therapy to avoid confounding due to legitimate delays to 
surgery in patients who receive neo-adjuvant therapy. All 
analyses were carried out using R, version 3.1.1 (packages 
finalfit, tidyverse, ggsurvplot).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results
20 006 patients were eligible for inclusion in 466 hospitals 
in 61 countries (figure 1). Of these patients, 1891 (9·5%) 
were from 17 UMICs and 2249 (11·2%) were from 
12 LMICs. A wide range of patients, tumours, and 
operations were included. The most common tumour 
types included were breast (n=3896; 19·5%), head and 
neck (n=3517; 17·6%), colon (n=3428; 17·1%), and 
gynaecological (n=2169; 10·8%). Distribution of patients 
and cancers across income groups and countries is 
shown in the appendix (pp 8–9).
Of patients planned for cancer surgery during the 
COVID-19 pandemic, 4521 (22·6%) of 20 006 were 
awaiting surgery during a period of light restrictions, 
3646 (18·2%) during moderate lockdowns, and 
11 827 (59·1%) during full lockdowns (n=12 missing data; 
appendix p 4). The proportion of patients awaiting 
surgery in full lockdowns was higher in areas with high 
than low community SARS-CoV-2 case notification rates 
and in UMICs and LMICs than in high-income countries 
(appendix p 10). Patients awaiting surgery during light 
restrictions had a lower mean number of weeks in full 
lockdown (2·4 weeks [SD 1·7]) compared with patients 
awaiting surgery during moderate (5·5 weeks [2·9]) or 
full lockdowns (12·7 weeks [5·4]; p<0·0001, from one-
way ANOVA).
Most patients (16 975 [84·8%] of 20 006) had a plan to 
progress straight to surgery (no neoadjuvant therapy), 
with 1900 (9·5%) receiving standard care neoadjuvant 
therapy, and 1131 (5·7%) receiving a COVID-19 decision 
for neoadjuvant therapy. During full lockdowns, patients 
were more likely to have a COVID-19 decision for 
neoadjuvant therapy than during moderate lockdowns or 
light restrictions (appendix p 3).
During the COVID-19 pandemic, 2003 (10·0%) of 
20 006 patients did not undergo their planned surgery by 
the end of follow-up (figure 2; appendix p 12). Patients 
awaiting surgery during periods of light restrictions had 
a lower rate of non-operation (26 [0·6%] of 4521) than 
those in moderate lockdowns (201 [5·5%] of 3646) or full 
lockdowns (1775 [15·0%] of 11 827; appendix p 5). 
Figure 2: Effects of lockdowns on surgical capacity
(A) Differences in resilience of surgical systems across income settings by COVID-19 stringency index group. 
Percentages represent proportion operated by group. (B) Kaplan-Meier plot demonstrating proportion of patients 
remaining non-operated over time from cancer diagnosis grouped by COVID-19 stringency index group. 
Plot censored at 28 weeks maximum follow-up from cancer diagnosis. Shading represents this represents the 
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Figure 3: Multivariable Cox 
proportional hazards model 
of factors associated with 
non-operation during 
COVID-19
19 832 in dataframe, 
19 066 in model, 766 missing. 
17 597 (91·8%) of 
19 066 patients included in 
this model were operated by 
the end of follow-up. Missing 
data are described in the 
appendix (p 10), as well as the 
full model (p 12). 
ASA=American Society of 
Anesthesiologists Physical 
Status Classification System. 
ECOG=Eastern Cooperative 
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1775 (88·7%) of 2003 patients who remained non-
operated were in regions with full lockdowns 
(appendix p 11). The baseline rate of non-operation was 
low across all income settings during periods of light 
restrictions (22 [0·5%] of 4089 in high-income countries; 
one [0·4%] of 228 in UMICs; three [1·5%] of 
204 in LMICs), and high during periods of full lock-
down (1188 [13·7%] of 8644 in high-income countries; 
139 [10·5%] of 1329 in UMICs; 448 [24·2%] of 
1854 in LMICs). At 12 weeks after diagnosis, 581 [12·8%] 
of 4520 patients under light restrictions remained non-
operated, 720 (19·9%) of 3622 patients during moderate 
lockdowns, and 4752 (40·7%) of 11 678 patients during 
full lockdowns (figure 2). After multivariable adjustment, 
both moderate (HR 0·81, 95% CI 0·77–0·84; p<0·0001) 
and full lock downs (HR 0·51, 0·50–0·53; p<0·0001) 
were associated with a lower likelihood of a patient 
receiving their planned cancer surgery (figure 3; 
appendix p 10). This was con sistent across planned 
sensitivity analyses (appendix pp 13–16). The overall level 
of missingness was low (<1%) for all variables included 
in the models.
Being in an LMIC, increasing frailty (Eastern 
Cooperative Oncology Group 1 or ≥2), comorbidity 
(Revised Cardiac Risk Index ≥3), and having locally 
advanced or nodal disease, or both, were all independently 
associated with increased likelihood of non-operation. 
There was significant variability in the likelihood of 
non-operation by cancer site. Where the primary 
outcome definition was revised to include elective 
surgery only, both UMICs and LMICs were observed to 
have a higher adjusted non-operation rates than high-
income countries (appendix p 13). The effect of lockdown 
on non-operation differed by income group, with LMICs 
broadly less likely to operate at a given level of lockdown 
compared with the high-income group (appendix p 15). 
Patients waiting for surgery in LMICs during full 
lockdowns were most likely to remain non-operated 
compared with patients in LMICs during light 
restrictions (HR 0·41, 95% CI 0·38–0·44; p<0·0001; 
appendix p 16). In the secondary analysis, waiting for 
surgery for 5–6 weeks or more in full lockdown was 
associated with a reduced likelihood of a patient 
undergoing their cancer operation compared with 
0 weeks in full lockdown (5–6 weeks in full lockdown 
HR 0·86, 95% CI 0·80–0·93, p<0·0001; appendix p 6).
Patients younger than 50 years were less likely than 
patients 50 years and older to receive their planned 
surgery across several sensitivity analyses. Patients 
planned to have surgery aged younger than 50 years 
were more commonly from LMICs than UMICs 
or high-income countries commonly from LMICs 
(appendix pp 18–19). In a sensitivity analysis including 
only patients older than 50 years, the effect of lockdowns 
on surgical capacity remained consistent with the 
primary result (ie, moderate and full lockdowns were 
associated with a significant increase in the odds of 
non-operation compared with light restrictions; 
appendix p 20).
Increasing SARS-CoV-2 case notification rates were 
associated with increasing non-operation rates (appendix 
p 21). Both moderate and full lockdowns were consistently 
associated with an increased likelihood of non-operation, 
even after adjustment for local SARS-CoV-2 rates 
(appendix p 22). The largest magnitude of effect was seen 
when transitioning from light restrictions or moderate 
lockdowns to full lockdowns across all income and 
SARS-CoV-2 case notification rate groups. LMICs were 
particularly fragile to increasing SARS-CoV-2 rates and 
full lockdowns, with a non-operation rate of 381 (58·7%) 
of 649 (appendix p 21).
By the end of the follow-up (median 23 weeks, 
IQR 16–30), 2003 patients had not undergone planned 
surgery. 453 (22·6%) of 2003 patients had been formally 
re-staged. Detection of new metastatic disease is shown 
in the appendix (p 26).
Of non-operated patients for whom data were available 
(n=2001; two missing data), all had at least one COVID-
19-related reason provided for non-operation (table 1); 
most commonly this involved a team decision to delay 
surgery during COVID-19 due to individual patient risk 
(1456 [72·8%] of 2001). 533 (26·6%) of 2001 patients were 
provided an alternative treatment modality as a result of 
COVID-19. 306 (15·3%) patients had at least one non-
COVID-19-related reason provided for non-operation. 
All patients
COVID-19 related
Multidisciplinary team decision to delay surgery due to patient risk during COVID-19 1456 (72·8%)
Change to alternative treatment modality because of COVID-19 533 (26·6%)
Patient choice to avoid surgery during COVID-19 pandemic 460 (23·0%)
Ongoing neoadjuvant therapy (COVID decision) 378 (18·9%)
No bed, critical care bed, or operating room space available due to COVID-19 299 (14·9%)
Change of recommendations in society guidelines related to COVID-19 220 (11·0%)
Patient unable to travel to hospital related to COVID-19 140 (7·0%)
Collateral impact on supporting services causing delay 24 (1·2%)
Patient delayed due to SARS-CoV-2 infection 23 (1·1%)
Died of COVID-19 while waiting for surgery 14 (0·6%)
Total 2001 (100·0%)
Non-COVID-19 related
Progression to unresectable disease 179 (8·9%)
Delay due to other unrelated medical or surgical condition 59 (2·9%)
Died unrelated to COVID-19 while waiting for surgery 34 (1·7%)
Patient unable to afford surgery 24 (1·2%)
Patient choice to avoid surgery unrelated to COVID-19 35 (1·7%)
Total 306 (15·3%)
We anticipated that decisions to delay or cancel surgery during COVID-19 would be complex. Therefore, selecting more 
than one reason for non-operation during the follow-up window for each patient was permitted. One patient could 
have both one or more COVID-19-related and non-COVID-19-related reasons selected. Where it was unclear whether a 
reason was directly COVID-related (eg, disease progression) this was classified as not COVID-19-related. Two patients 
(0·1%) had no reasons given for non-operation during the follow-up window selected (missing data). Proportions are 
therefore expressed as a percentage of 2001 non-operated patients and with data available.
Table 1: Reasons that patients did not received planned surgery
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179 (8·9%) patients progressed to unresectable disease. 
48 (2·4%) patients died before their planned surgery 
(14 due to COVID-19-related complications, and 34 due to 
non-COVID-19-related causes).
Delays from diagnosis to operation were observed 
during full lockdowns for operated patients (n=18 003) 
across all neoadjuvant treatment groups (figure 4). In 
patients who went straight to surgery (no neoadjuvant 
therapy; 15 622 [86·3%] of 18 003), full lockdown was 
associated with 2001 [23·8%] of 11 827 patients not 
receiving surgery within 12 weeks of diagnosis compared 
with 317 (10·4%) of 3646 patients during moderate 
lockdowns, and 374 (9·1%) of 4521 patients under light 
restrictions (appendix p 25). For these patients, each 
additional week in lockdown was associated with treat-
ment delay (p<0·0001; figure 4). Increasing SARS-CoV-2 
case notifi cation rates were also associated with increased 
delays beyond 12 weeks across income groups, with the 
longest delays observed in UMICs and LMICs during 
periods with high SARS-CoV-2 rates (appendix p 23). The 
point of system friction was different across different 
income groups (appendix p 7). Full lockdown was asso-
ciated with an increased interval from decision to surgery 
across all settings compared with both light restrictions 
and moderate lockdown (figure 4; appendix p 24).
In patients who went straight to surgery (n=15 622), 
postoperative histopathological and clinical outcomes 
during light restrictions, moderate lockdowns, and full 
lockdowns were similar (table 2). Characteristics and 
outcomes of patients by interval from diagnosis to 
operation are in the appendix (pp 25–26). Variation in 
outcomes by income group are shown in the appendix 
(p 27).
Discussion
The design of this study allowed a holistic overview of 
different health systems’ surgical capacity and outcomes 
during lockdowns. The analysis allowed a direct 
comparison during full and moderate lockdowns to 
periods with light restrictions, taking account of the 
dynamic nature of government policies, where different 
patients from the same country were exposed to different 
lockdown states. During full lockdowns, one in seven 
patients did not receive their planned operation, all of 
whom had a pandemic-related reason for non-operation. 
This finding was robust, and consistent in sensitivity 
analyses. In a secondary analysis, awaiting surgery in a 
full lockdown for greater than 6 weeks was associated 
with an increased likelihood of non-operation. These 
data reveal the fragility of elective cancer surgery to 
lockdowns, which was independent of both local 
SARS-CoV-2 rates and case-mix. Patients with cancer in 
LMICs, of increasing frailty, or with advanced disease 
were most vulnerable to lockdown effects. Capacity for 
major elective cancer should be part of every country’s 
strategy to address whole-population health needs and 
prevent further collateral harm.
Identifying at-risk groups allows targeted system 
strengthening during both COVID-19 lockdowns and 
future pandemics. Firstly, vulnerable patient groups 
(eg, those with a poorer performance score, more cardiac 
comorbidities, or advanced cancers) were all less likely to 
receive surgery. Secondly, certain operation types that 
Figure 4: Lockdown and delay to surgery
(A) Delay from diagnosis to surgery during lockdowns (according to COVID-19 stringency index group) by 
neoadjuvant therapy group. Percentages represent proportion of operated patients who were in each interval from 
diagnosis to operation group. (B) Weeks in full lockdown and interval from cancer diagnosis to operation. 
Plot displays patients who went straight to surgery (no neoadjuvant therapy only). Full lockdown defined as a 
COVID-19 stringency index score of more than 60. Plotted line represents a smoothed conditional mean from a 
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require more intensive perioperative care, including 
those for oesophageal and pancreatic cancer, were at 
increased risk of cancellation. Thirdly, patients in LMICs 
were less likely to undergo surgery during lockdowns 
and SARS-CoV-2 surges, which included a high 
proportion of young patients (<50 years). Protected 
elective surgical capacity might include protected 
COVID-19-free path ways (including dedicated surgical, 
anaesthetic, and theatre staff) within larger hospitals, or 
smaller bespoke elective surgery units that function as 
part of cancer treatment networks.20 This also requires 
long-term investment in surge capacity for the acute care 
workforce and formal operational planning to manage 
public health emergencies without major disruption to 
elective care (further details are in the appendix p 64). 
Together, protected elective surgical capacity might allow 
essential elective surgery to continue despite external 
system shocks.20
The least resilient systems were in LMIC settings, 
exacerbating resource scarcity and capacity issues that 
were present prepandemic in the management of 
non-communicable diseases.11,21 Elective cancer surgery 
systems in LMICs are typically under pressure from a high 
burden of expedited and emergency presentations.11,15,21 
This pressure was seen in our study, where the likelihood 
of non-operation was higher in both UMICs and LMICs, 
despite patients being younger and having fewer 
comorbidities. These young patients were more frequently 
affected by financial and geographical causes for non-
operation, revealing a particularly vulnerable group. 
Measures to strengthen the security of global elective 
cancer surgery must be implemented across all settings, 
and as a priority in LMICs.6 Despite data demonstrating 
the safety of neoadjuvant treatment during COVID-19, the 
overall rate of neoadjuvant therapy as standard care or a 
COVID-19 decision was low (15·2%). This low rate might 
represent safety concerns or highlight capacity issues 
elsewhere in the cancer care pathway.22 Developing robust 
pathways from diagnosis through to definitive surgical 
treatment, supported by public health teams and financial 
protection mechanisms, will help to create both pandemic-
proof and more equitable systems.
Although we did not find an increase in the positive 
resection margin rate or new metastatic disease 
associated with increasing delays, these were highly 
selected patients and with short-term follow-up only. The 
high proportion of patients who did not receive planned 
surgery reveals the true extent of potential harm. This 
part of our analysis focussed on patients who were 
treated without neoadjuvant therapy, who are likely to 
represent the group at highest risk from unplanned 
delays. Evidence from modelling studies and meta-
analyses suggest that 4-week incremental delays before 
surgery are associated with increased rates of recurrence 
and excess mortality.13 Taken together, patients who 
experienced a delay to surgery during the COVID-19 
pandemic might warrant strategies that support closer 
follow-up for metastatic disease. It is possible that there 
will be a reverse trend towards worsening cancer survival 
rates over the next 5 years as a consequence of these 
capacity issues, although the present study was not 
designed to directly capture these long-term effects. We 
acknowledge that for some cancer types, neoadjuvant 
therapy has equivalent outcomes to the adjuvant 
application of the same treatment and might be a 
reasonable strategy to safely delay treatment where this is 
required (eg, endocrine therapy for oestrogen-receptor-
positive breast cancers).23 The impact of changes to 
neoadjuvant treatment pathways and both short-term 
and long-term oncological outcomes requires further 
exploration.
This study had several further limitations. First, effects 
seen during lockdowns could be interpreted as normal 
practice, which would have occurred outside of the 
pandemic era. We dealt with this by including an internal 
comparison (light restrictions), which is akin to normal 
conditions and carried a non-operation rate of 0·5%. We 













R0 3471 (83·7%) 2619 (85·8%) 7238 (86·3%) 13 328 (85·5%) 0·0011
R1 381 (9·3%) 223 (7·4%) 581 (6·9%) 1185 (7·7%) ··
R2 79 (1·9%) 61 (2·0%) 157 (1·9%) 297 (1·9%) ··
Pathology unavailable 214 (5·2%) 147 (4·8%) 407 (4·8%) 768 (4·9%) ··
Missing 7 7 19 33 ··
Resectable disease at time of surgery
Resectable 4069 (98·0%) 2967 (97·1%) 8213 (97·8%) 15 249 (97·7%) 0·045
Unresectable 81 (2·0%) 90 (2·9%) 187 (2·2%) 358 (2·3%) ··
Unknown 2 0 2 4 ··
Pre-operative cancer-related complication requiring emergency surgery‡
Elective 4071 (98·2%) 2989 (97·8%) 8199 (97·8%) 15 259 (97·9%) 0·27
Emergency 74 (1·8%) 67 (2·2%) 185 (2·2%) 326 (2·1%) ··
30-day SARS-CoV-2 infection rate‡
No 4083 (98·3%) 3039 (99·4%) 8362 (99·5%) 15 484 (99·2%) <0·0001
Yes 69 (1·7%) 18 (0·6%) 40 (0·5%) 127 (0·8%) ··
30-day postoperative mortality rate‡
No 4080 (98·3%) 3016 (98·7%) 8307 (99·0%) 15 403 (98·8%) 0·0045
Yes 70 (1·7%) 41 (1·3%) 84 (1·0%) 195 (1·2%) ··
Missing 2 0 11 13 ··
New detection of metastatic disease§
No 2191 (98·3%) 1625 (98·3%) 4946 (98·2%) 8762 (98·2%) 0·87
Yes 38 (1·7%) 28 (1·7%) 93 (1·8%) 159 (1·8%) ··
Missing 7 5 15 27 ··
Data are n (%) or n. Patients with metastatic disease at baseline removed from denominator (N=8957). Percentages 
presented by column total; missing data are excluded. R0=no microscopic or macroscopic disease. R1=microscopic 
disease at the margin. R2=macroscopic disease at the margin. *11 missing this data point. †χ2 comparing light versus 
moderate versus full lockdowns for each outcome. ‡Subgroups defined in the appendix (p 62). §Detailed data on 
detection of new metastatic disease not collected for liver, pancreatic, breast, and gynaecological cancers.
Table 2: Outcomes across COVID-19 stringency index groups for patients going straight to surgery 
(no neoadjuvant therapy)
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were overwhelmingly COVID-19 related. Second, we used 
the Oxford COVID-19 Stringency Index to define 
lockdowns,1 calculated for each patient as the median 
average during their wait for surgery. Although this index 
has been validated, it is not yet widely used, and the 
COVIDSurg Collaborative is an early adopter of this metric 
for research purposes. This health policy measure 
demonstrated association with patient level outcomes in 
our dataset. However, we used an aggregate summary 
statistic that did not reflect all changes in policy during the 
study period. More work is required to understand the best 
method to apply this measure in future epidemiological 
studies. Third, as part of the exposure period to lockdowns 
occurred after study entry (ie, decision for surgery), this 
might have been subject to future information bias, where 
patients remaining non-operated for a longer time might 
have been more likely to await surgery during different 
lockdown states, therefore have a central tendency in their 
median average score.24 Fourth, this study required 
prospective capture of team decision making, which might 
have been subject to biases, although the scale and diversity 
of the study mitigated against this. Fifth, definition of 
SARS-CoV-2 rates is dependent on testing performed and 
reported, so might vary at global scale.17,18 We present 
exploratory analyses around SARS-CoV-2 rates stratified by 
income setting and provide sensitivity analyses to 
demonstrate that findings were robust. Sixth, we did not 
present more detailed analyses of between-country or 
within-country variation. Despite the large numbers in this 
study, individual numbers per country were low enough to 
risk type 1 error through multiple hypothesis testing. 
Seventh, in this analysis we did not explore different 
hospital types or delay in care for different cancers. There 
might have been hospitals that shutdown completely and 
did not take part in this study, meaning outcomes might 
have been worse. There might be specialty specific findings 
that allow future strategies to become stratified—eg, 
patients with rectal and prostate cancer might benefit from 
scaling up alternative neoadjuvant treatments; breast 
and gynaecological cancer surgery might be amenable to 
day case pathways; kidney, bladder, thoracic, and oeso-
phagogastric surgery might require the advanced support 
of surgical units with critical care facilities; colon cancer 
could be performed in standalone surgical units. Eighth, 
we did not capture data on delays to diagnosis. Lockdowns 
are a system-level issue and high friction in diagnostic 
pathways was likely to have led to an increasing number of 
tumours left undetected in the community.25 When 
considering resilience of a complete elective surgery 
system, there is a vital role of timely diagnostics in 
preventing harm, which might be just as important as 
delays between diagnosis and surgery. Finally, cancer care 
is just one component of a functioning health system. 
When making policy decisions about resourcing to 
improve resilience, cancer must be balanced with other 
high-burden conditions (eg, cardiovascular and cerebro-
vascular disease).26
At the time of publication, lockdowns of varying 
magnitude remain in place across many countries 
around the world, and further measures might be 
imposed related to novel variants of concern and 
variability in vaccine availability around the world 
(appendix p 64); however, threats to stable elective 
surgical systems are not limited to COVID-19; other viral 
pandemics, seasonal pressures, and natural disasters all 
affect surgical patients on an annual and recurring basis. 
The lessons from this study might be used to inform 
surgical system strengthening both during the COVID-19 
pandemic and beyond.
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